Clinical Research Directory
Browse clinical research sites, groups, and studies.
Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
Sponsor: Haukeland University Hospital
Summary
ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.
Official title: Rituximab and Ocrelizumab in Serum With Multiple Sclerosis (ROS-MS)
Key Details
Gender
All
Age Range
18 Years - 60 Years
Study Type
OBSERVATIONAL
Enrollment
60
Start Date
2021-03-15
Completion Date
2027-12-31
Last Updated
2024-10-29
Healthy Volunteers
No
Conditions
Interventions
Blood samples for PK
Blood sampled for pharmacokinetic study
Blood samples for PK
Blood samples before, shortly after infusion of already assigned/ongoing treatment as well as after 2, 4, 8, 12, 24 weeks for serum conc. measurements.
Locations (1)
Haukeland University Hospital, Deparment of medical biochemistry and pharmacology
Bergen, Vestland, Norway